Celldex Therapeutics


Cowen Reiterates Upbeat View Of Celldex Therapeutics As It Wins FDA ‘Breakthrough’ Status

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares are up 17.

Company Update (NASDAQ:CLDX): Celldex’s Rindopepimut Receives FDA Breakthrough Therapy Designation

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced that the U.

Cantor Maintains Buy On Celldex Therapeutics Following Data Presentations At SABCS

In a research report issued today, Cantor analyst Mara Goldstein maintained a Buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) with a $33 price …

Roth Capital Comments On Celldex Following Enrollment Completion Of Phase III ACT IV Study

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a …

Celldex: Merck’s Immune Checkpoint Inhibitor Doesn’t Threat Glemba, Says Cowen

In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $26 price target. …

Cowen Maintains Outperform On Celldex Following Initiation Of Phase II Trial Of Glembatumumab In Advanced Melanoma

Cowen analyst Boris Peaker maintained an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $26, following the news that the …

Roth Capital Maintains Buy On Celldex Following Initiation Of CDX-011 Phase II Study

Roth Capital analyst Joseph Pantginis maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $43 price target, as the company announced the initiation of …

Roth Capital Raises Celldex Therapeutics Price Target As Rindopepimut Delivered A Strong Showing At SNO

In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and increased his price …

UPDATE: Brean Capital Maintains Buy On Celldex Therapeutics Following Positive Avastin-Naïve Data

In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $35 price …

Celldex Remains Undervalued As Rindopepimut Remains Unappreciated, Says Oppenheimer

In a research report released today, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $36 price target, …